FORMULATION OF DOSATINIB ENCAPSULATED NANOCARRIERS BY BOX-BEHNKEN DESIGN OF EXPERIMENTS AND DETERMINATION OF EFFICACY IN MCF-& CELL LINE

Abstract

Dosatinib is a strong chemotherapy medicine that is used to treat many types of cancer, such as ovarian, breast, and non-small cell lung cancer. However, it is hard to employ in clinical settings since it doesn't dissolve well in water, has serious side effects, and may cause multi-drug resistance. Researchers are exploring for innovative ways to distribute drugs to get around these problems, and Dosatinib-loaded hyaluronic acid (HA) micelles are getting a lot of interest. HA is a naturally occurring polymer that is very soluble in water, safe for living things, and breaks down easily. It is found in the extracellular matrix. HA can self-assemble into micelles in water when it is chemically changed with hydrophobic substances. After that, hydrophobic medicines like Dosatinib can be put in the midst of these HA micelles.  Dosatinib -loaded hyaluronic acid Pluronic (DSB-HA-PF127) micelles represent a significant advancement in cancer nanomedicine, offering advantages over conventional chemotherapy through targeted distribution, enhanced efficacy, and reduced unwanted effects. This study seeks to enhance the efficacy of Dosatinib by encapsulating it within hyaluronic acid micelles, thereby prolonging its half-life in the bloodstream. The Box-Behnken experimental design was utilised to enhance the formula.